FDA approves AngioVue optical coherence tomography angiography imaging system for age-related macular degeneration- Optovue
Optovue has announced FDA clearance and immediate U.S. commercial availability of the AngioVue optical coherence tomography angiography (OCTA) Imaging System, a technology that provides a non-invasive way to visualize abnormal blood vessels in the retina to help physicians determine an appropriate course of treatment in patients with diseases such as age-related macular degeneration.
The AngioVue System acquires a single image that complements the current angiography imaging standard, fluorescein angiography (FA), but with a number of advantages. Unlike FA, the AngioVue System does not require the use of dye injections, which can often obscure the target anatomy and can lead to side effects and other complications associated with dye-based, invasive procedures. The system was launched in the EU in November 2015.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins